Clinical trials: Anthracycline-induced Cardiac Toxicity
Breast Cancer, Cardiotoxicity
Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab
The aim of the study is to analyze the protective impact on the cardiac damage of beta blockers and ACE inhibitors for breast cancer patients treated with anthracyclines-based chemotherapy with or without trastuzumab.
- Trial name
- SAFE (NCT02236806)
- Testing
- Bisoprolol, Ramipril
- Where
- Italy
- Volunteers
- 262 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Anthracycline-induced Cardiac Toxicity, Lymphoma
REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs
Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic PreConditioning (RIPC) in Lymphoma patients receiving…
- Trial name
- RESILIENCE (NCT05223413)
- Testing
- RIPC
- Where
- 24 sites in Denmark, France and 4 more
- Volunteers
- 608 people
- Sponsor
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Anthracycline Induced Cardiotoxicity
Late Anthracycline Induced Cardiotoxicity- Childhood Cancer Survivors
Anthracyclines treat up to 60% of childhood malignancies with remarkable improvements survival rates. Unfortunately anthracyclines are associated with an increased cardiomyopathy risk.
- Trial name
- NCT04852965
- Where
- United Kingdom
- Volunteers
- 103 people
- Sponsor
- Queen's University, Belfast
Cardiotoxicity
Effect of Remote Ischaemic Conditioning in Oncology Patients
Cancer survival has improved steadily due to earlier detection and treatment. Despite the established efficacy of anthracycline chemotherapy, its damaging effects on the heart (cardiotoxicity) limits treatment and confers acute…
- Trial name
- ERIC-ONC (NCT02471885)
- Testing
- Remote Ischaemic Conditioning
- Where
- United Kingdom
- Volunteers
- 128 people
- Sponsor
- University College, London
Anthracycline Related Cardiotoxicity in Breast Cancer
Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction
Cardiomyopathy is a major complication of doxorubicin (DOX) chemotherapy, and 10-21% of breast cancer patients receiving DOX experience compromised cardiac function.
- Trial name
- NCT03934905
- Testing
- sulforaphane
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Texas Tech University Health Sciences Center
Breast Cancer (Early Breast Cancer), Cardiotoxicity
Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer
The goal of this observational study is to evaluate cardiac side effects in women with early-stage breast cancer who receive systemic chemotherapy and/or anti-HER2 therapy as part of their standard cancer care.
- Conditions
- Breast Cancer (Early Breast Cancer), Cardiotoxicity, Cancer Therapy-Related Cardiac Dysfunction
- Trial name
- C-BREAST-01 (NCT07588425)
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Fatih GURLER
Breast Cancer
Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity
The purpose of this study is to evaluate whether dapagliflozin reduces chemotherapy-induced cardiotoxicity in participants with breast cancer treated with (neo-)adjuvant Anthracycline-based chemotherapy +/- trastuzumab.
- Trial name
- PROTECT (NCT06341842)
- Testing
- Dapagliflozin 10mg Tab
- Where
- Italy
- Volunteers
- 316 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Breast Cancer, Lymphoma, Large B-Cell, Diffuse
Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines
As the cancer-related prognosis improves thanks to recent advances in cancer-targeted therapies, the prognostic burden of chemotherapy-related complications - including cardiotoxicity - is increasingly recognised.
- Conditions
- Breast Cancer, Lymphoma, Large B-Cell, Diffuse, Cardiotoxicity, Left Ventricular Dysfunction
- Trial name
- CONTROL (NCT05728632)
- Testing
- Nebivolol
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Giulio Stefanini
Cardiac Dysfunction, Cardiovascular Diseases
Cardiac Dysfunction in Childhood Cancer Survivors
This multicenter, prospective cohort study evaluates early cardiac dysfunction in adult survivors of childhood cancer. The hypothesis of this study is that cardiac dysfunction can be detected earlier when using speckle tracking…
- Conditions
- Cardiac Dysfunction, Cardiovascular Diseases, Childhood Cancer
- Trial name
- Cardio-Onco (NCT03790943)
- Testing
- cardiac assessment
- Where
- 6 sites in Switzerland
- Volunteers
- 500 people
- Sponsor
- University of Bern
Anthracycline Induced Cardiotoxicity
Spironolactone Against Anthracycline-induced Cardiomyopathy
This study sought to investigate the whether spironolactone protects the heart against anthracycline-induced cardiotoxicity.
- Trial name
- NCT02053974
- Testing
- Spironolactone
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people
- Sponsor
- TC Erciyes University
Cardiotoxicity, Anthracycline-induced Cardiotoxicity
Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy
The goal of the trial is the early detection of cardiotoxicity in patients treated with anthracycline-based chemotherapy. Current diagnostics, such as troponin T, NT-pro-BNP, electrocardiogram, and echocardiography, are not able…
- Trial name
- CMR-Onko (NCT07528586)
- Testing
- CMR based measurement of cardiotoxicity, biosampling for scientific research in study-specific biobank
- Where
- Germany
- Volunteers
- 93 people
- Sponsor
- Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Cardiotoxicity Induced by Drug Therapy for Breast Cancer
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.
- Trial name
- START (NCT06214195)
- Testing
- Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Zhejiang Cancer Hospital
Heart Failure, Anthracycline-induced Cardiac Toxicity
Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients
The goal of this randomized, double-blind, placebo-controlled clinical trial is to determine whether dapagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, can help prevent anthracycline-induced cardiotoxicity caused…
- Conditions
- Heart Failure, Anthracycline-induced Cardiac Toxicity, Endothelial Function (FMD), Arterial Stiffness
- Trial name
- Alpaca (NCT07245069)
- Testing
- Dapagliflozin 10 mg
- Where
- Slovenia
- Volunteers
- 100 people
- Sponsor
- University Medical Centre Ljubljana
Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin
Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG
Management of patients with lymphoma is based on the administration of a chemotherapy containing anthracyclines (ATC), and allows cure rates of 65% to 80% at 5 years.
- Trial name
- DETECT (NCT04892667)
- Testing
- Intervention
- Where
- France
- Volunteers
- 128 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Heart Failure
Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy
Breast cancer is very common and afflicts 1 in 9 North American women. The treatment of breast cancer often requires the use of chemotherapy including "anthracyclines".
- Trial name
- NCT00247975
- Testing
- L-carnitine
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Breast Cancer
Cardiotoxicity of Cancer Therapy (CCT)
The objective of this study is to define the clinical significance of mechanistic biomarkers (including Neuregulin-1Beta) and novel echocardiographic measures of cardiac function in predicting the incident risk of cancer therapy…
- Trial name
- NCT01173341
- Testing
- Echocardiography, Blood Collection, Symptoms Questionnaire
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Anthracyclines-Induced Cardiotoxicity, Cardiotoxicity
Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity
Anthracyclines, such as doxorubicin, are effective anticancer agents but may cause dose-dependent cardiac injury, including early changes in left ventricular function and cardiac biomarkers.
- Trial name
- DAPA-AIC (NCT06888505)
- Testing
- Dapagliflozin (Forxiga)
- Where
- Iraq
- Volunteers
- 94 people
- Sponsor
- Hawler Medical University
Cardiomyopathy Due to Drug
Myocardial Fibrosis Identification in Patients With Anthracycline-induced Cardiotoxicity
This is an interventional study for patients who had developed Anthracycline-Induced Cardiotoxicity (AIC) during or after anthracycline-containing therapy, referred to the Cardioncology Unit for heart failure treatment
- Trial name
- NCT06331806
- Testing
- Evaluation of myocardial fibrosis
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- European Institute of Oncology
Breast Cancer
Circulating MicroRNA as Biomarker of Cardiotoxicity in Breast Cancer
In the proposed project the investigators will asses whether changes in expression of selected circulating microRNAs in serum could comprise a sensitive and specific biomarker of cardiotoxicity in cancer patients treated with…
- Trial name
- NCT02065908
- Where
- 3 sites in Poland
- Volunteers
- 128 people
- Sponsor
- West Pomeranian Cancer Center
Breast Cancer, Non Hodgkin Lymphoma
PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?
PROACT will establish the effectiveness of the angiotensin-converting enzyme inhibitor (ACEI) enalapril maleate (enalapril) in preventing cardiotoxicity in patients with breast cancer and non-Hodgkin lymphoma undergoing adjuvant…
- Trial name
- PROACT (NCT03265574)
- Testing
- Enalapril
- Where
- United Kingdom
- Volunteers
- 111 people
- Sponsor
- South Tees Hospitals NHS Foundation Trust